ArticleEvidence-based complementary and alternative medicine : eCAM2012
Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice.
Article in Evidence-based complementary and alternative medicine : eCAM, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 70 citations in OpenAlex.
- Shikonin Modulates the NOD2/CARD9 Pathway to Ameliorate Ulcerative Colitis Through Inhibiting M1 Macrophage Polarization.Applied biochemistry and biotechnology · 2025Article
- Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases.Frontiers in pharmacology · 2023Review
- Medicinal plant-based drug delivery system for inflammatory bowel disease.Frontiers in pharmacology · 2023Review
- Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages.Frontiers in pharmacology · 2022Article
- Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.Molecules (Basel, Switzerland) · 2021Review
- Short-Chain Naphthoquinone Protects Against Both Acute and Spontaneous Chronic Murine Colitis by Alleviating Inflammatory Responses.Frontiers in pharmacology · 2021Article
- Article
- Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.Chinese medicine · 2020Review
- Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Anti-inflammatory effects of shikonin in human periodontal ligament cells.Pharmaceutical biology · 2018Article
- Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis.Cell host & microbe · 2018Article
- The Circadian Clock Controls Immune Checkpoint Pathway in Sepsis.Cell reports · 2018Article
- ALK is a therapeutic target for lethal sepsis.Science translational medicine · 2017Article
- The Impacts ofEvidence-based complementary and alternative medicine : eCAM · 2017Article
- PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation.Nature communications · 2016Article
- Plumbagin Protects Mice from Lethal Sepsis by Modulating Immunometabolism Upstream of PKM2.Molecular medicine (Cambridge, Mass.) · 2016Article
- Biosynthesis and molecular actions of specialized 1,4-naphthoquinone natural products produced by horticultural plants.Horticulture research · 2016Review
- Allicin Alleviates Dextran Sodium Sulfate- (DSS-) Induced Ulcerative Colitis in BALB/c Mice.Oxidative medicine and cellular longevity · 2015Article
- A review on chemical-induced inflammatory bowel disease models in rodents.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2014Review
- PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis.Nature communications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The naphthoquinone shikonin, a major component of the root of Lithospermum erythrorhizon, now is studied as an anti-inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/C mice by oral administration of 5% dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower in shikonin-treated mice than in the colitic group, as well as the myeloperoxidase activity. The expression of cyclooxygenase-2 was reduced by 75%, activation of NF-κB was reduced by 44%, and that of pSTAT-3 by 47%, as well as TNF-α, IL-1β, and IL-6 production. Similar results were obtained in primary macrophages culture. This is the first report of shikonin's ability to attenuate acute UC induced by DSS. Shikonin acts by blocking the activation of two major targets: NF-κB and STAT-3, and thus constitutes a promising potential therapeutic agent for the management of the inflammatory bowel disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.